Status:
COMPLETED
Evaluation of Pharmacokinetics and Safety Tolerability of Higher Doses of Rifampic
Lead Sponsor:
Kilimanjaro Clinical Research Institute
Collaborating Sponsors:
European and Developing Countries Clinical Trials Partnership (EDCTP)
Conditions:
Clinical Trial
Eligibility:
All Genders
1-14 years
Phase:
PHASE1
PHASE2
Brief Summary
Tuberculosis in children is a major public health problem and it contributes 10% of the total TB cases worldwide. TB treatment outcomes in children are challenged by insufficient consideration of the ...
Detailed Description
Tuberculosis (TB) in children is a major public health problem . It has a global estimate of \>100,000 deaths per year and is included in the top ten causes of mortality in children worldwide. Childre...
Eligibility Criteria
Inclusion
- Children aged 1 to 14 years with newly diagnosed Tuberculosis
Exclusion
- Children with elevated liver function
- Children allergic to first line anti-TB drugs
Key Trial Info
Start Date :
July 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2023
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT04437836
Start Date
July 1 2019
End Date
December 31 2023
Last Update
February 15 2024
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Kilimanjaro Clinical Research Institute
Moshi, Kilimanjaro, Tanzania, +255
2
Hydom Hospital
Babati, Manyara Region, Tanzania
3
Mt. Meru Hospital
Arusha, Tanzania
4
Huruma Hospital
Moshi, Tanzania